GlobalData on MSN1d
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...
Macular Degeneration Treatment Market Size is Projected to Reach USD 18.59 Billion by 2033, Growing at a CAGR of 7.06%: Straits Research
The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...
A Patient’s Guide to Macular Degeneration: Symptoms and Treatment
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...
ophthalmologytimes7d
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Business Wire7d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Quad-City Times2d
Eye Surgeons Associates: The macula matters: What you need to know about age-related macular degeneration (AMD)
Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
The American Journal of Managed Care7d
FDA Approves Ranibizumab Implant in Treatment of DME
The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...
Daily6d
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...